Renalys Pharma Reports Promising Results from Phase III Study of Sparsentan for IgA Nephropathy in Japan Renalys Pharma revealed positive outcomes from a Phase III trial of sparsentan in Japanese IgA nephropathy patients, indicating a potential new treatment option in Japan.

Renalys Pharma Reports Promising Results from Phase III Study of Sparsentan for IgA Nephropathy in Japan #Japan #Tokyo #Sparsentan #Renalys_Pharma #IgA_nephropathy

Chugai Pharmaceutical Takes Significant Step by Acquiring Renalys Pharma Chugai Pharmaceutical has announced its strategic acquisition of Renalys Pharma, enhancing its capabilities in chronic kidney disease treatments across Asia.

Chugai Pharmaceutical Takes Significant Step by Acquiring Renalys Pharma #Japan #Tokyo #Sparsentan #Renalys_Pharma #Chugai_Pharmaceutical

Renalys Pharma Provides Financial Support for Alport Syndrome Registry Study in Japan Renalys Pharma is excited to announce its financial backing for a significant study on Alport Syndrome, initiated by the Japanese Society for Pediatric Nephrology.

Renalys Pharma Provides Financial Support for Alport Syndrome Registry Study in Japan #Japan #Tokyo #Renalys_Pharma #Alport_Syndrome #Pediatric_Nephrology

Renalys Pharma Finalizes Agreement with Japan's PMDA for Clinical Trials of Sparsentan Renalys Pharma announces a key agreement with Japan's PMDA for Phase III trials of Sparsentan aimed at treating FSGS and Alport Syndrome, with a focus on enhancing kidney health.

Renalys Pharma Finalizes Agreement with Japan's PMDA for Clinical Trials of Sparsentan #Japan #Tokyo #Sparsentan #Renalys_Pharma #FSGS

Renalys Pharma Completes Patient Enrollment for Sparsentan Clinical Trial in Japan Renalys Pharma has completed patient enrollment for the Phase III clinical trial of sparsentan, aimed at treating IgA nephropathy in Japan, aiming for timely patient care.

Renalys Pharma Completes Patient Enrollment for Sparsentan Clinical Trial in Japan #Japan #Tokyo #Sparsentan #Renalys_Pharma #IgA_nephropathy

Renalys Pharma's Sparsentan Secures Orphan Drug Status for IgA Nephropathy in Japan Renalys Pharma announces that Sparsentan has received Orphan Drug Designation in Japan for treating IgA nephropathy, a significant step towards addressing unmet medical needs.

Renalys Pharma's Sparsentan Secures Orphan Drug Status for IgA Nephropathy in Japan #Japan #Tokyo #Sparsentan #Renalys_Pharma #IgA_nephropathy